Literature DB >> 30779860

Cost-Effectiveness of Osteoporosis Screening Using Biomechanical Computed Tomography for Patients With a Previous Abdominal CT.

Maria Pisu1, David L Kopperdahl2, Cora E Lewis3, Kenneth G Saag4, Tony M Keaveny5.   

Abstract

Osteoporosis screening rates by DXA are low (9.5% women, 1.7% men) in the US Medicare population aged 65 years and older. Addressing this care gap, we estimated the benefits of a validated osteoporosis diagnostic test suitable for patients age 65 years and older with an abdominal computed tomography (CT) scan taken for any indication but without a recent DXA. Our analysis assessed a hypothetical cohort of 1000 such patients in a given year, and followed them for 5 years. Separately for each sex, we used Markov modeling to compare two mutually exclusive scenarios: (i) utilizing the CT scans, perform one-time "biomechanical computed tomography" (BCT) analysis to identify high-risk patients on the basis of both femoral strength and hip BMD T-scores; (ii) ignore the CT scan, and rely instead on usual care, consisting of future annual DXA screening at typical Medicare rates. For patients with findings indicative of osteoporosis, 50% underwent 2 years of treatment with alendronate. We found that BCT provided greater clinical benefit at lower cost for both sexes than usual care. In our base case, compared to usual care, BCT prevented hip fractures over a 5-year window (3.1 per 1000 women; 1.9 per 1000 men) and increased quality-adjusted life years (2.95 per 1000 women; 1.48 per 1000 men). Efficacy and savings increased further for higher-risk patient pools, greater treatment adherence, and longer treatment duration. When the sensitivity and specificity of BCT were set to those for DXA, the prevented hip fractures versus usual care remained high (2.7 per 1000 women; 1.5 per 1000 men), indicating the importance of high screening rates on clinical efficacy. Therefore, for patients with a previously taken abdominal CT and without a recent DXA, osteoporosis screening using biomechanical computed tomography may be a cost-effective alternative to current usual care.
© 2019 American Society for Bone and Mineral Research. © 2019 American Society for Bone and Mineral Research.

Entities:  

Keywords:  COST EFFECTIVENESS; DXA; HEALTH ECONOMICS; OSTEOPOROSIS; SCREENING

Year:  2019        PMID: 30779860      PMCID: PMC6687393          DOI: 10.1002/jbmr.3700

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  68 in total

1.  Effect and offset of effect of treatments for hip fracture on health outcomes.

Authors:  B Jonsson; J Kanis; A Dawson; A Oden; O Johnell
Journal:  Osteoporos Int       Date:  1999       Impact factor: 4.507

2.  Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions.

Authors:  A N Tosteson; B Jönsson; D T Grima; B J O'Brien; D M Black; J D Adachi
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

3.  Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.

Authors:  D M Black; D E Thompson; D C Bauer; K Ensrud; T Musliner; M C Hochberg; M C Nevitt; S Suryawanshi; S R Cummings
Journal:  J Clin Endocrinol Metab       Date:  2000-11       Impact factor: 5.958

4.  Direct medical costs attributable to osteoporotic fractures.

Authors:  S E Gabriel; A N A Tosteson; C L Leibson; C S Crowson; G R Pond; C S Hammond; L J Melton
Journal:  Osteoporos Int       Date:  2002       Impact factor: 4.507

Review 5.  Estimating hip fracture morbidity, mortality and costs.

Authors:  R Scott Braithwaite; Nananda F Col; John B Wong
Journal:  J Am Geriatr Soc       Date:  2003-03       Impact factor: 5.562

Review 6.  Epidemiology and outcomes of osteoporotic fractures.

Authors:  Steven R Cummings; L Joseph Melton
Journal:  Lancet       Date:  2002-05-18       Impact factor: 79.321

7.  Occurrence of hip fractures and socioeconomic position.

Authors:  W E Bacon; W C Hadden
Journal:  J Aging Health       Date:  2000-05

8.  Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study.

Authors:  S C E Schuit; M van der Klift; A E A M Weel; C E D H de Laet; H Burger; E Seeman; A Hofman; A G Uitterlinden; J P T M van Leeuwen; H A P Pols
Journal:  Bone       Date:  2004-01       Impact factor: 4.398

9.  Hip fracture incidence in nursing home residents and community-dwelling older people, Washington State, 1993-1995.

Authors:  Jonathan R Sugarman; Frederick A Connell; Amy Hansen; Steven D Helgerson; Michael C Jessup; Helan Lee
Journal:  J Am Geriatr Soc       Date:  2002-10       Impact factor: 5.562

10.  Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study.

Authors:  Cynthia L Leibson; Anna N A Tosteson; Sherine E Gabriel; Jeanine E Ransom; L Joseph Melton
Journal:  J Am Geriatr Soc       Date:  2002-10       Impact factor: 5.562

View more
  3 in total

1.  Osteoporosis screening using computed tomography for men with prostate cancer: results of a prospective study.

Authors:  Andrew M McDonald; Eddy S Yang; Kenneth G Saag; Emily B Levitan; Nicole C Wright; John B Fiveash; Soroush Rais-Bahrami; Smita Bhatia
Journal:  Arch Osteoporos       Date:  2020-02-29       Impact factor: 2.617

Review 2.  Opportunistic diagnosis of osteoporosis, fragile bone strength and vertebral fractures from routine CT scans; a review of approved technology systems and pathways to implementation.

Authors:  Veena Aggarwal; Christina Maslen; Richard L Abel; Pinaki Bhattacharya; Paul A Bromiley; Emma M Clark; Juliet E Compston; Nicola Crabtree; Jennifer S Gregory; Eleni P Kariki; Nicholas C Harvey; Kate A Ward; Kenneth E S Poole
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-07-10       Impact factor: 5.346

Review 3.  Biomechanical Computed Tomography analysis (BCT) for clinical assessment of osteoporosis.

Authors:  T M Keaveny; B L Clarke; F Cosman; E S Orwoll; E S Siris; S Khosla; M L Bouxsein
Journal:  Osteoporos Int       Date:  2020-04-26       Impact factor: 5.071

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.